VGXI: News
VGXI Announces Grand Opening Celebration for New Headquarters and Manufacturing Facility
Specialized plasmid DNA contract manufacturer VGXI, Inc. announces date for the Grand Opening celebration of its new headquarters and expanded manufacturing facility in Conroe, TX.[...]
Read More
VGXI Celebrates First Look Event at New Manufacturing Facility
VGXI opened the doors of its new headquarters and manufacturing facility on 09Apr22 to provide friends and employee families a first look inside and outside[...]
Read More
VGXI Official COVID-19 Statement
To our Valued Clients and Business Partners, VGXI’s top priority is to continue delivering the highest quality DNA products and services while ensuring the security[...]
Read More
VGXI Partner IMM Announces $12M NIH Grant to Support Phase 1 Clinical Trial of a DNA Vaccine for the Prevention of Alzheimer’s Disease
Texas-based CDMO VGXI, Inc. is excited to announce that its partner, The Institute for Molecular Medicine, has recently been awarded a $12 million NIA grant[...]
Read More
VGXI New Manufacturing Facility Achieves Construction Milestones In Advance of 2022 Operational Date
Specialized GMP contract manufacturer VGXI, Inc. announced multiple construction milestones have been reached for its new headquarters and expanded manufacturing facility in Conroe, TX. The[...]
Read More
VGXI, Inc. Partners with Rare Trait Hope Fund in Support of Gene Therapy for Rare Disease, AGU
Industry leading plasmid DNA Manufacturer VGXI, Inc. partners with Rare Trait Hope Fund in support of a gene therapy for the rare genetic disease, Aspartylglucosaminuria[...]
Read More
VGXI Celebrates Topping Out for New Headquarters and Manufacturing Facility in Conroe, TX
Texas-based plasmid DNA Manufacturer VGXI, Inc. Celebrates the Topping Out for its New Headquarters and Expanded Manufacturing Facility. The Woodlands, TX – VGXI, Inc., a[...]
Read More
VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies
Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical[...]
Read More